| ||
| Pfizer Lung-Cancer Drug Seen Approved in Q4 Barron's Amongst the multitude of lung-cancer presentations, Pfizer's oral crizotinib (an ALK inhibitor) was touted as a breakthrough and was reflective of the focus on personalized medicine. Crizotinib was designed for non-small cell lung-cancer (NSCLC) ... See all stories on this topic » | ||
| ||
| Mature Autologous Dendritic Cell Vaccines in Advanced Non-Small Cell Lung ... 7thSpace Interactive (press release) Overall therapeutic outcomes of advanced non-small-cell lung cancer (NSCLC) are poor. The dendritic cell (DC) immunotherapy has been developed as a new strategy for the treatment of lung cancer. The purpose of this study was to evaluate the feasibility ... See all stories on this topic » | ||
| Proteins may explain why some people exposed to asbestos develop mesothelioma Mesothelioma.com Asbestos is a highly carcinogenic mineral fiber that is known to cause several types of cancer, but predominantly lung cancer and mesothelioma, which affects that protective lining of the lungs, heart, chest and abdomen. In fact, prolonged asbestos ... See all stories on this topic » | ||
| ESU alum Randal Scott included on sesquicentennial scientist list Emporia Gazette Since the company's founding in 2000, work has focused on breast cancer. Additional work with colon cancer began in 2009. In January of this year, work began with prostate cancer. The company's researchers also are studying non-small cell lung cancer, ... See all stories on this topic » |
This once a day Google Alert is brought to you by Google.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment